Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$9.88 +0.3%	$10.36	$5.42 ▼ $22.49	$108.78M	1.59	263,344 shs	105,141 shs
ATE Antibe Therapeutics	C$0.30	C$0.56	C$0.15 ▼ C$1.23	C$15.54M	0.12	135,475 shs	N/A
FRX Forest Road Acquisition		$10.30	$9.72 ▼ $18.20	$450M	N/A	2.07 million shs	40,482 shs
IMV IMV		$0.66	$0.48 ▼ $12.70	$9.63M	0.95	233,607 shs	44,800 shs
RPHM Reneo Pharmaceuticals	$1.73 -1.7%	$1.66	$0.98 ▼ $11.30	$57.82M	0.24	279,810 shs	27,627 shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+8.93%	-19.02%	+9.78%	-15.48%	-33.24%
ATE Antibe Therapeutics	0.00%	0.00%	-27.16%	-66.85%	-46.36%
FRX Forest Road Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
IMV IMV	0.00%	0.00%	0.00%	0.00%	+22.78%
RPHM Reneo Pharmaceuticals	-0.56%	+3.53%	+6.67%	+9.32%	-80.31%

Claim Your Complimentary Bitcoin Reward (Ad)

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	1.6543 of 5 stars	3.4	1.0	0.0	0.0	3.1	1.7	0.6
ATE Antibe Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMV IMV	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RPHM Reneo Pharmaceuticals	0.8677 of 5 stars	2.9	0.0	0.0	0.0	0.6	2.5	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.75	Moderate Buy	$27.75	180.87% Upside
ATE Antibe Therapeutics	2.00	Hold	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A
IMV IMV	2.00	Hold	N/A	N/A
RPHM Reneo Pharmaceuticals	1.88	Reduce	$18.14	948.41% Upside

Current Analyst Ratings

Latest IMV, ANVS, RPHM, ATE, and FRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
3/21/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
3/4/2024	ATE Antibe Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/28/2024	ANVS Annovis Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$9.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.73) per share	N/A
ATE Antibe Therapeutics	C$9.71M	1.60	C$0.48 per share	0.61	C$0.49 per share	0.60
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	$0.56 per share	N/A
IMV IMV	$330K	0.00	N/A	N/A	($0.69) per share	0.00
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	$2.66 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$56.20M	-$6.22	N/A	N/A	N/A	N/A	-446.06%	-257.97%	5/9/2024 (Estimated)
ATE Antibe Therapeutics	-C$18.24M	-C$0.35	N/A	∞	N/A	N/A	-52.72%	-19.13%	7/4/2024 (Estimated)
FRX Forest Road Acquisition	-$7.92M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IMV IMV	-$37.99M	-$4.59	N/A	N/A	N/A	-11,547.42%	-12,695.41%	-104.84%	N/A
RPHM Reneo Pharmaceuticals	-$77.39M	-$2.52	N/A	N/A	N/A	N/A	-73.14%	-63.85%	5/9/2024 (Estimated)

Latest IMV, ANVS, RPHM, ATE, and FRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/14/2024	Q3 2024	ATE Antibe Therapeutics	-C$0.12	-C$0.08	+C$0.04	-C$0.08	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
ATE Antibe Therapeutics	C$0.05	16.95%	N/A	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A
IMV IMV	N/A	N/A	N/A	N/A	N/A
RPHM Reneo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	2.39	2.39
ATE Antibe Therapeutics	0.29	10.06	9.58
FRX Forest Road Acquisition	N/A	0.37	0.37
IMV IMV	N/A	2.93	2.93
RPHM Reneo Pharmaceuticals	N/A	5.87	5.87

Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
ATE Antibe Therapeutics	N/A
FRX Forest Road Acquisition	N/A
IMV IMV	15.37%
RPHM Reneo Pharmaceuticals	90.98%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	38.30%
ATE Antibe Therapeutics	7.94%
FRX Forest Road Acquisition	N/A
IMV IMV	0.33%
RPHM Reneo Pharmaceuticals	17.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	5	11.01 million	6.79 million	Optionable
ATE Antibe Therapeutics	11	52.67 million	N/A	Not Optionable
FRX Forest Road Acquisition	N/A	37.50 million	N/A	Not Optionable
IMV IMV	97	11.71 million	11.67 million	Optionable
RPHM Reneo Pharmaceuticals	55	33.42 million	27.44 million	Optionable

IMV, ANVS, RPHM, ATE, and FRX Headlines

Source	Headline
	Reneo Pharmaceuticals Inc. thestreet.com - April 14 at 1:20 PM
	Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 0.6% marketbeat.com - April 3 at 2:35 AM
	Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target markets.businessinsider.com - March 31 at 7:14 PM
	Reneo Pharmaceuticals: Q4 Earnings Insights benzinga.com - March 28 at 4:09 PM
	RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023 investorplace.com - March 28 at 2:01 PM
	Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update finanznachrichten.de - March 28 at 10:52 AM
	Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update globenewswire.com - March 28 at 7:35 AM
	Reneo Pharmaceuticals, Inc. (RPHM) uk.finance.yahoo.com - February 14 at 12:17 AM
	Reneo Pharmaceuticals, Inc. (RPHM) uk.finance.yahoo.com - February 14 at 12:17 AM
	Reneo Pharmaceuticals Inc (RPHM) investing.com - January 30 at 1:28 AM
	Reneo Shares Dive 83% After Drug Fails Trial ocbj.com - January 8 at 8:25 PM
	Sharp increase in RPHM’s short interest leads to surge in days-to-cover ratio knoxdaily.com - January 4 at 12:32 PM
	Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session msn.com - December 27 at 3:51 PM
	Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC) markets.businessinsider.com - December 19 at 5:49 PM
	Hold Rating on Reneo Pharmaceuticals Following Lead Drug Trial Failure and Strategic Uncertainty markets.businessinsider.com - December 16 at 9:33 AM
	Jefferies Downgrades Reneo Pharmaceuticals (RPHM) msn.com - December 16 at 9:33 AM
	Reneo in trouble after trial failure scotches mavodelpar hopes thepharmaletter.com - December 15 at 12:31 PM
	Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study finance.yahoo.com - December 15 at 12:31 PM
	Reneo Pharmaceuticals just downgraded at BofA, here's why realmoney.thestreet.com - December 15 at 7:30 AM
	5 Analysts Have This to Say About Reneo Pharmaceuticals markets.businessinsider.com - December 15 at 7:30 AM
	Reneo Pharmaceuticals just downgraded at Piper Sandler, here's why realmoney.thestreet.com - December 15 at 1:35 AM
	Reneo Pharmaceuticals just downgraded at Leerink, here's why realmoney.thestreet.com - December 15 at 1:35 AM
	Rare disease company Reneo stops all development bioworld.com - December 14 at 8:35 PM
	Reneo Pharma Hits All-Time Low on Job Cuts, Halted Mavodelpar Development marketwatch.com - December 14 at 3:34 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
3 Cheap Stocks That Shouldn’t Be Cheap for Long
March 26, 2024 9:49 AM
View 3 Cheap Stocks That Shouldn’t Be Cheap for Long
3 High Dividend Stocks to Replace Lower Savings Yields Ahead
April 9, 2024 9:15 AM
View 3 High Dividend Stocks to Replace Lower Savings Yields Ahead
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
March 24, 2024 1:50 PM
View Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer

All Headlines

Company Descriptions

Annovis Bio

NYSE:ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Antibe Therapeutics

TSE:ATE

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Forest Road Acquisition

NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

IMV

NASDAQ:IMV

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Reneo Pharmaceuticals

NASDAQ:RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial